home / stock / iccm / iccm quote
Last: | $1.19 |
---|---|
Change Percent: | 0.83% |
Open: | $1.19 |
Close: | $1.19 |
High: | $1.2 |
Low: | $1.16 |
Volume: | 64,057 |
Last Trade Date Time: | 04/30/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.19 | $1.19 | $1.19 | $1.2 | $1.16 | 64,057 | 04-30-2024 |
$1.2 | $1.2 | $1.2 | $1.21 | $1.17 | 69,995 | 04-29-2024 |
$1.2 | $1.21 | $1.2 | $1.2182 | $1.18 | 60,561 | 04-26-2024 |
$1.19 | $1.2 | $1.19 | $1.21 | $1.18 | 75,361 | 04-25-2024 |
$1.22 | $1.25 | $1.22 | $1.25 | $1.1901 | 94,212 | 04-24-2024 |
$1.22 | $1.22 | $1.22 | $1.2399 | $1.19 | 65,824 | 04-23-2024 |
$1.22 | $1.26 | $1.22 | $1.26 | $1.18 | 101,211 | 04-22-2024 |
$1.21 | $1.23 | $1.21 | $1.2383 | $1.17 | 124,649 | 04-19-2024 |
$1.23 | $1.28 | $1.23 | $1.28 | $1.23 | 105,942 | 04-18-2024 |
$1.29 | $1.05 | $1.29 | $1.3 | $1.03 | 1,457,418 | 04-17-2024 |
$1.3 | $1.35 | $1.3 | $1.35 | $1.28 | 862,233 | 04-16-2024 |
$1.35 | $1.36 | $1.35 | $1.45 | $1.26 | 12,264,669 | 04-15-2024 |
$1.25 | $1.24 | $1.25 | $1.2649 | $1.22 | 84,173 | 04-12-2024 |
$1.25 | $1.26 | $1.25 | $1.26 | $1.24 | 41,354 | 04-11-2024 |
$1.24 | $1.22 | $1.24 | $1.25 | $1.22 | 56,126 | 04-10-2024 |
$1.25 | $1.25 | $1.25 | $1.25 | $1.23 | 67,360 | 04-09-2024 |
$1.25 | $1.23 | $1.25 | $1.252 | $1.22 | 92,993 | 04-08-2024 |
$1.25 | $1.26 | $1.25 | $1.26 | $1.21 | 79,564 | 04-05-2024 |
$1.25 | $1.3 | $1.25 | $1.3 | $1.2406 | 80,861 | 04-04-2024 |
$1.25 | $1.31 | $1.25 | $1.3262 | $1.2 | 251,237 | 04-03-2024 |
News, Short Squeeze, Breakout and More Instantly...
IceCure Medical Ltd. Company Name:
ICCM Stock Symbol:
NASDAQ Market:
2024-04-15 10:06:29 ET DENVER, Colo., Apr 15, 2024 ( 247marketnews.com )- IceCure Medical Ltd. (NASDAQ: ICCM ) stated that it submitted final data to the U.S. Food and Drug Administration (“FDA”) requesting marketing authorization for ProSense, which received the FDA...
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer PR Newswire Data presentation ...
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance PR Newswire Co...